Vext Science (FRA:VV5) Stock Based Compensation: €0.03 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VV5 Vext Science Inc FRA:VV5
67 GF Score
Price €0.14
GF Value €0.94
! 3 Warning Signs
View Full Analysis

What is Vext Science Stock Based Compensation?

Vext Science FRA:VV5 +2.14% 67 Stock Based Compensation is €0.03 Mil as of Mar. 2026. GuruFocus rates FRA:VV5 with a GF Score™ of 67/100 and a GF Value™ of €0.94. The stock has 3 warning signs investors should review.

Vext Science's Stock Based Compensation for the three months ended in Mar. 2026 was €0.01 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €0.03 Mil.

Vext Science Stock Based Compensation Related Terms

Vext Science Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Vext Science's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vext Science Stock Based Compensation Chart

Vext Science Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 0.84 1.37 0.35 0.67 0.04

Vext Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.01 -0.00 0.01
FRA:VV5
67GF Score
Vext Science Inc FRA:VV5
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vext Science Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.03 Mil.

What does a Stock Based Compensation of €0.03 Mil mean?
Vext Science (FRA:VV5) has a Stock Based Compensation of €0.03 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vext Science and its competitors.
Is Vext Science's Stock Based Compensation too high?
Vext Science's current Stock Based Compensation is €0.03 Mil. Overall, Vext Science has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's Stock Based Compensation compare to ZTS?
Vext Science's Stock Based Compensation of €0.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vext Science and its competitors. Vext Science's current Stock Based Compensation is €0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current Stock Based Compensation of €0.03 Mil. The stock's GF Value™ is €0.94, compared to a current price of €0.14 — trading 84.8% below its estimated fair value. The current Stock Based Compensation is €0.03 Mil. Vext Science's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current Stock Based Compensation is €0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vext Science (FRA:VV5) Overvalued in 2026?

Based on GuruFocus' analysis, Vext Science stock appears to be undervalued. The current stock price of €0.14 is trading 84.8% below its estimated GF Value™ of €0.94.

Key valuation signals for FRA:VV5:

  • Stock Based Compensation: €0.03 Mil
  • GF Value™: €0.94 vs. price of €0.14 (84.8% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vext Science Business Description

Other Exchanges VEXTF:USAVEXT:Canada
Address 4152 N. 39th Avenue, Admin, Phoenix, AZ, USA, 85019
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
67GF Score

Get the complete analysis for FRA:VV5

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.94
GF Value